248.37 USD
-2.69
1.07%
At close Jul 7, 4:00 PM EDT
After hours
248.37
+0.00
0.00%
1 day
-1.07%
5 days
-3.11%
1 month
-3.17%
3 months
-5.74%
6 months
-1.53%
Year to date
3.49%
1 year
38.55%
5 years
29.92%
10 years
501.38%
 

About: Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products.

Employees: 4,500

0
Funds holding %
of 7,311 funds
0
Analysts bullish %
of 6 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

502% more call options, than puts

Call options by funds: $95.8M | Put options by funds: $15.9M

136% more first-time investments, than exits

New positions opened: 92 | Existing positions closed: 39

50% more funds holding in top 10

Funds holding in top 10: 4 [Q4 2024] → 6 (+2) [Q1 2025]

13% more funds holding

Funds holding: 367 [Q4 2024] → 415 (+48) [Q1 2025]

11% more capital invested

Capital invested by funds: $8.3B [Q4 2024] → $9.24B (+$945M) [Q1 2025]

9% more repeat investments, than reductions

Existing positions increased: 141 | Existing positions reduced: 129

1.28% less ownership

Funds ownership: 90.97% [Q4 2024] → 89.69% (-1.28%) [Q1 2025]

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$315
27%
upside
Avg. target
$325
31%
upside
High target
$330
33%
upside

6 analyst ratings

positive
100%
neutral
0%
negative
0%
RBC Capital
Shagun Singh
33%upside
$330
Outperform
Maintained
24 Apr 2025
UBS
Priya Sachdeva
33%upside
$330
Buy
Maintained
24 Apr 2025
Truist Securities
David Rescott
33%upside
$330
Buy
Maintained
24 Apr 2025
Stifel
Mathew Blackman
28%upside
$318
Buy
Maintained
24 Apr 2025
Wells Fargo
Larry Biegelsen
27%upside
$315
Overweight
Maintained
24 Apr 2025

Financial journalist opinion

Based on 7 articles about PEN published over the past 30 days

Neutral
PRNewsWire
6 days ago
Penumbra, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call for July 29, 2025
ALAMEDA, Calif. , July 1, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the second quarter 2025 after market close on Tuesday, July 29, 2025 at 4:30 PM Eastern Time.
Penumbra, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call for July 29, 2025
Positive
Seeking Alpha
1 week ago
Penumbra: AI Meets Aspiration - Why The Stock Is A Structural Winner
Penumbra's AI-guided aspiration system and scalable platform uniquely position it as a leader in stroke and PE intervention, justifying a Buy rating. First-mover advantage in intelligent thrombectomy, expanding European reimbursement, and an aging population create strong long-term growth tailwinds. Despite premium valuation multiples, PEN's innovation, ecosystem, and divestiture of non-core assets support its growth and margin expansion potential.
Penumbra: AI Meets Aspiration - Why The Stock Is A Structural Winner
Positive
Zacks Investment Research
1 week ago
ITGR vs. PEN: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Instruments stocks have likely encountered both Integer (ITGR) and Penumbra (PEN). But which of these two stocks presents investors with the better value opportunity right now?
ITGR vs. PEN: Which Stock Is the Better Value Option?
Neutral
PRNewsWire
3 weeks ago
Penumbra, Inc. Announces Completion of Enrollment for Landmark STORM-PE Randomized Controlled Trial
STORM-PE is a first-of-its-kind clinical trial comparing computer assisted vacuum thrombectomy (CAVT™) using Penumbra's Lightning Flash™ with anticoagulation versus anticoagulation alone in the treatment of acute intermediate-high risk pulmonary embolism ALAMEDA, Calif. , June 16, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced the completion of enrollment in the STORM-PE clinical trial.
Penumbra, Inc. Announces Completion of Enrollment for Landmark STORM-PE Randomized Controlled Trial
Positive
Zacks Investment Research
4 weeks ago
ITGR or PEN: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Instruments stocks have likely encountered both Integer (ITGR) and Penumbra (PEN). But which of these two stocks is more attractive to value investors?
ITGR or PEN: Which Is the Better Value Stock Right Now?
Negative
Zacks Investment Research
4 weeks ago
Zacks Industry Outlook Penumbra, Integer and AngioDynamics
Zacks names PEN, ITGR and ANGO as medical device stocks riding genAI advances, despite global and inflationary headwinds.
Zacks Industry Outlook Penumbra, Integer and AngioDynamics
Positive
Zacks Investment Research
4 weeks ago
PEN Stock Rises Following the Launch of Ruby XL System
Penumbra launches FDA-cleared Ruby XL System to bring advanced coil technology to high-flow embolization procedures.
PEN Stock Rises Following the Launch of Ruby XL System
Positive
Zacks Investment Research
1 month ago
3 Medical Instruments Stocks Winning Big With GenAI Amid Global Gloom
PEN, ITGR and ANGO from the Zacks Medical Instruments industry are worth buying based on genAI adoption, strategic developments and strong fundamentals. Yet, geopolitical complications and supply issues mar prospects.
3 Medical Instruments Stocks Winning Big With GenAI Amid Global Gloom
Neutral
PRNewsWire
1 month ago
Penumbra Introduces the Ruby® XL System - the Longest, Largest, and Softest Coil on the Market for Vascular Embolization
ALAMEDA, Calif. , June 5, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) announced the U.S. Food and Drug Administration (FDA) clearance and launch of the Ruby® XL System, the longest, largest and softest coil on the marketi.
Penumbra Introduces the Ruby® XL System - the Longest, Largest, and Softest Coil on the Market for Vascular Embolization
Negative
Zacks Investment Research
1 month ago
Why Is Penumbra (PEN) Down 10.6% Since Last Earnings Report?
Penumbra (PEN) reported earnings 30 days ago. What's next for the stock?
Why Is Penumbra (PEN) Down 10.6% Since Last Earnings Report?
Charts implemented using Lightweight Charts™